Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Core Viewpoint - Telomir Pharmaceuticals, Inc. has announced positive results from its GLP toxicology and safety pharmacology studies for its lead candidate, Telomir-1, indicating no treatment-related adverse toxicity and consistent systemic exposure following oral administration [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies targeting epigenetic and metabolic drivers of cancer and age-related diseases [1] Group 2: Study Results - The comprehensive series of IND-enabling GLP studies showed no treatment-related adverse toxicity [1] - Consistent systemic exposure was observed following oral administration of Telomir-1 [1]